Akèy › Kansè Poumon ki pa ti selil › Pennsylvania
Etid klinik pou Kansè Poumon ki pa ti selil nan Pennsylvania
103 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Pennsylvania.
Vil nan Pennsylvania
- Philadelphia51 etid
- Pittsburgh48 etid
- York15 etid
- Allentown14 etid
- Harrisburg12 etid
- Reading9 etid
- Lancaster7 etid
- Scranton6 etid
- Chambersburg6 etid
- Erie5 etid
- New Castle4 etid
- Hazleton4 etid
- Williamsport3 etid
Tèks ofisyèl etid la (Anglè)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- UPMC-Heritage Valley Health System Beaver, Beaver
- ak 53 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- St. Lukes Hospital and Health Network ( Site 0186), Bethlehem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06623422A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- UPMC-Heritage Valley Health System Beaver, Beaver
- Carlisle Regional Cancer Center, Carlisle
- UPMC Hillman Cancer Center Erie, Erie
- ak 17 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #104, Hershey
- Exelixis Clinical Site #98, Philadelphia
- Exelixis Clinical Site #32, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06780085A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Perelman Center for Advanced Medicine ( Site 3205), Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07513376A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- ak 14 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Lancaster General Hospital, Lancaster
- Local Institution - 0028, Pittsburgh
- WellSpan Oncology Research, York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Alliance Cancer Specialists, Sellersville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Spoknwrd Clinical Trials /ID# 273776, Easton
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Penn State Milton S. Hershey Medical Center, Hershey
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alliance Cancer Specialists, PC, Bensalem
- Consultants in Medical Oncology and Hematology, P.C., Broomall
- Alliance Cancer Specialists, PC, Doylestown
- ak 5 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312137A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Alliance Cancer Specialists - Media, Media
- Guthrie Medical Group, Sayre
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 25, 2026 · NCT05920356Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Philadelphia
- Research Site, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06218914A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Health Northeast, Philadelphia
- McGlinn Cancer Institute Reading Hospital, West Reading
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- University of Pennsylvania, Philadelphia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667908A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Fountain Hill
- Research Site, Kittanning
- Research Site, Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- Jefferson Hospital Northeast, Philadelphia
- AHN Allegheny General Hospital, Pittsburgh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- Lancaster General Hospital (UPenn), Lancaster
- Guthrie Foundation, Sayre
- Cancer Care Associates of York (CCAY), York
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- ak 5 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- Local Institution - 0504, Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06561386Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Pittsburgh
Ap rekriteFaz 2
Laj 18 a 95 · Tout sèks · Mizajou Sep 23, 2026 · NCT05061550Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Lankenau Medical Center, Paoli
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07028489Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Guthrie Robert Packer Hospital /ID# 270316, Sayre
- Cancer Care Associates Of York /ID# 270971, York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06568939Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Hospital of the University of Pennsylvania, Philadelphia
- West Penn Allegheny Health, Pittsburgh
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07100080An External Control Arm Study in Non-Small Cell Lung Cancer
- Main Line Health, Wynnewood
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174388A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0688, Easton
- WellSpan Oncology Research, York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06875310A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Hershey
- Research Site, York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Philadelphia
- Clinical Study Site, Pittsburgh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- UPMC, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Allegheny Singer, Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- St. Luke's University Health Network, Bethlehem
- Allegheny Cancer Center, Pittsburgh
- Reading Hospital - McGlinn Cancer Institute, West Reading
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06793215A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06345729Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.